Imugene Limited
Clinical trials sponsored by Imugene Limited, explained in plain language.
-
Experimental virus therapy targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tested a new treatment called onCARlytics (CF33-CD19), a virus designed to infect and kill cancer cells, given alone or with the immune drug blinatumomab. The trial enrolled 25 adults with advanced solid tumors that had not responded to at least two prior t…
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 23, 2026 23:53 UTC
-
Experimental lung cancer vaccine trial halted early
Disease control TerminatedThis early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or with other cancer drugs to see if it was safe and could shrink tumors. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Experimental virus therapy VAXINIA tested in advanced cancer patients
Disease control TerminatedThis early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC